Literature DB >> 12000711

Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification.

Raymond Tubbs1, James Pettay, Marek Skacel, Richard Powell, Mark Stoler, Patrick Roche, James Hainfeld.   

Abstract

Fluorescence in situ hybridization (FISH) represents an excellent method for profiling gene amplification in situ, but correlation with tissue morphology is difficult because of dark-field visualization. Validation of a bright-field assay for assessment of HER-2/neu gene amplification was investigated. Streptavidin-Nanogold was used to generate bright-field gene copy signals using GoldEnhance gold-based autometallography, catalyzed reported deposition, and a biotin-labeled probe. One hundred cases of invasive breast carcinoma were evaluated for which FISH gene copy results, and mRNA and oncoprotein gene expression, were known. Autometallographic signals were qualitatively evaluable without the use of oil immersion microscopy. Results correlated well with indirect and direct label FISH. Autometallographic gold-based in situ hybridization represents a promising bright-field assay for the assessment of HER-2/neu gene amplification.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12000711      PMCID: PMC1850888          DOI: 10.1016/S0002-9440(10)61106-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message.

Authors:  R R Tubbs; J D Pettay; P C Roche; M H Stoler; R B Jenkins; T M Grogan
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

2.  Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

Authors:  A D Seidman; M N Fornier; F J Esteva; L Tan; S Kaptain; A Bach; K S Panageas; C Arroyo; V Valero; V Currie; T Gilewski; M Theodoulou; M E Moynahan; M Moasser; N Sklarin; M Dickler; G D'Andrea; M Cristofanilli; E Rivera; G N Hortobagyi; L Norton; C A Hudis
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

3.  c-erbB-2 amplification in node-negative human breast cancer.

Authors:  J S Ro; A el-Naggar; J Y Ro; M Blick; D Frye; G Fraschini; H Fritsche; G Hortobagyi
Journal:  Cancer Res       Date:  1989-12-15       Impact factor: 12.701

4.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

5.  Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization.

Authors:  A Lebeau; D Deimling; C Kaltz; A Sendelhofert; A Iff; B Luthardt; M Untch; U Löhrs
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

6.  Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer.

Authors:  O P Kallioniemi; K Holli; T Visakorpi; T Koivula; H H Helin; J J Isola
Journal:  Int J Cancer       Date:  1991-11-11       Impact factor: 7.396

7.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

8.  Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.

Authors:  H Tsuda; S Hirohashi; Y Shimosato; T Hirota; S Tsugane; H Yamamoto; N Miyajima; K Toyoshima; T Yamamoto; J Yokota
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

9.  Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.

Authors:  S Toikkanen; H Helin; J Isola; H Joensuu
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544

10.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

Authors:  B A Gusterson; R D Gelber; A Goldhirsch; K N Price; J Säve-Söderborgh; R Anbazhagan; J Styles; C M Rudenstam; R Golouh; R Reed
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544

View more
  7 in total

1.  Guidelines for HER2 testing in the UK.

Authors:  E D Hsi; R R Tubbs
Journal:  J Clin Pathol       Date:  2004-03       Impact factor: 3.411

2.  Novel bright field molecular morphology methods for detection of HER2 gene amplification.

Authors:  Raymond Tubbs; James Pettay; David Hicks; Marek Skacel; Richard Powell; Tom Grogan; James Hainfeld
Journal:  J Mol Histol       Date:  2004-08       Impact factor: 2.611

3.  Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer.

Authors:  Cornelia Hauser-Kronberger; Nadia Dandachi
Journal:  J Mol Histol       Date:  2004-08       Impact factor: 2.611

Review 4.  Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma.

Authors:  Aaron M Gruver; Ziad Peerwani; Raymond R Tubbs
Journal:  J Clin Pathol       Date:  2010-03       Impact factor: 3.411

5.  Genotyping of phenotypically defined cells in neoplasia: enhanced immunoFISH via tyramide signal amplification (TSA) segregates immunophenotypically-defined cell populations for gated genotyping.

Authors:  Raymond R Tubbs; Kingshuk Das; James R Cook; James D Pettay; Patrick C Roche; Thomas Grogan
Journal:  J Mol Histol       Date:  2007-01-05       Impact factor: 3.156

6.  Testing for HER2 in Breast Cancer: A Continuing Evolution.

Authors:  Sejal Shah; Beiyun Chen
Journal:  Patholog Res Int       Date:  2010-12-06

7.  Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH).

Authors:  Hiroaki Nitta; Beatrice Hauss-Wegrzyniak; Megan Lehrkamp; Adrian E Murillo; Fabien Gaire; Michael Farrell; Eric Walk; Frederique Penault-Llorca; Masafumi Kurosumi; Manfred Dietel; Lin Wang; Margaret Loftus; James Pettay; Raymond R Tubbs; Thomas M Grogan
Journal:  Diagn Pathol       Date:  2008-10-22       Impact factor: 2.644

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.